<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) is often associated with cardiovascular (CV) risk factors such as <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, on glycaemic control and CV risk factors </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This analysis included 675 Intent-to-Treat patients with T2DM [baseline (mean ± SD) HbA1c, 8.1 ± 1.2%; fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG), 166 ± 48 mg/dl; weight, 94.3 ± 19.4 kg; systolic/diastolic blood pressure (SBP/<z:chebi fb="4" ids="35861">DBP</z:chebi>), 129 ± 15/78 ± 9 mm Hg; total cholesterol, 178.5 ± 41.9 mg/dl; <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>), 100.1 ± 35.0 mg/dl; <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>), 44.5 ± 11.6 mg/dl; <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, 155.6 ± 3.3 mg/dl; alanine aminotransferase (ALT), 32.1 ± 19.5 U/l] treated with diet and exercise alone or in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, and/or thiazolidinedione who received 52 weeks of ExQW in four clinical trials </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: At 52 weeks, ExQW significantly improved HbA1c [mean (SE) change from baseline, -1.3 (0.05)%], FBG [-36.3 (2.02) mg/dl], body weight [-2.6 (0.19) kg], SBP/<z:chebi fb="4" ids="35861">DBP</z:chebi> [-3.6 (0.56) mm Hg/-1.2 (0.34) mm Hg], total cholesterol, -4.4 (1.33) mg/dl; <z:chebi fb="15" ids="39026">LDL</z:chebi>, -2.6 (1.08) mg/dl; <z:chebi fb="17" ids="39025">HDL</z:chebi>, 1.1 (0.31) mg/dl; <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, -7 (1.6)%], and ALT [-4.3 (0.71) IU/l] concentrations, with greater improvements in patients with elevated analyte levels at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Improvements were observed across a range of background antihyperglycaemia therapies </plain></SENT>
<SENT sid="5" pm="."><plain>Of patients completing 52 weeks, 19% achieved the composite American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association goal (HbA1c &lt; 7.0%, BP &lt; 130/80 mm Hg, <z:chebi fb="15" ids="39026">LDL</z:chebi> &lt; 100 mg/dl), compared to 1% at baseline </plain></SENT>
<SENT sid="6" pm="."><plain>Nearly half (48%) achieved HbA1c &lt; 7.0% without <z:mp ids='MP_0005456'>weight gain</z:mp> or major/minor <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002018'>Nausea</z:hpo> was the most frequent adverse event and was predominantly mild </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> was infrequent, and more common with a <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: With 52 weeks of ExQW, patients experienced sustained improvements in glycaemic control and CV risk factors, with an increased likelihood of achieving both a clinically relevant composite outcome (HbA1c &lt; 7% without <z:mp ids='MP_0005456'>weight gain</z:mp> or increased risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>) and a composite of key therapeutic goals (HbA1c &lt; 7%, BP &lt; 130/80 mm Hg, <z:chebi fb="15" ids="39026">LDL</z:chebi> &lt; 100 mg/dl) </plain></SENT>
</text></document>